A new analysis shows people with cancer treated with Xarelto (rivaroxaban) for blood clots had significantly fewer emergency room (ER) visits and lower healthcare costs- Bayer HealthCare + Janssen Pharma

A new analysis shows people with cancer treated with Xarelto (rivaroxaban) for blood clots had significantly fewer emergency room (ER) visits and lower healthcare costs at initiation of therapy than those given standard treatment. Also presented were economic research and real-world evidence confirming the overall safety and efficacy profile of Xarelto in this patient group. According to the analysis, fewer people had to go to the ER to start treatment with Xarelto than LMWH, demonstrating significant changes in practice and cost savings. In the first six months of the study, similar rates of people were sent to the ER to start anticoagulation treatment between the Xarelto and LMWH groups (71% vs. 63%, respectively). After those six months, there was a significant decrease in people starting treatment with Xarelto in the ER from 71% at baseline to 42% at one year (p=0.008) and 34% at 18 months (p=0.0001), which researchers attributed to physicians becoming more familiar with Xarelto. After one year, 18% of people who were prescribed XARELTO were managed by a simple telephone call, typically after a recent outpatient visit. Researchers also observed significant cost savings for people taking Xarelto, which was mainly due to the reduction in ER visits. The analysis was presented at the 2016 American Society of Hematology (ASH) Annual Meeting.